Stock MEDINCELL
Add to a list
To use this feature you must be a member
Log inSign up

MedinCell Stock LIQUIDNET SYSTEMS

Equities

FR0004065605

Pharmaceuticals

End-of-day quote LIQUIDNET SYSTEMS
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for MedinCell -.--% -.--%
05-15 Medincell: share price falls after disappointing clinical study CF
05-15 Transcript : MedinCell S.A. - Special Call

Financials

Sales 2024 * 13.96M 15.08M 20.75M Sales 2025 * 41.8M 45.15M 62.14M Capitalization 439M 475M 653M
Net income 2024 * -23M -24.84M -34.19M Net income 2025 * 1M 1.08M 1.49M EV / Sales 2024 * 35 x
Net Debt 2024 * 48.73M 52.63M 72.44M Net Debt 2025 * 58.83M 63.54M 87.45M EV / Sales 2025 * 11.9 x
P/E ratio 2024 *
-16.6 x
P/E ratio 2025 *
-284 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.05%
More Fundamentals * Assessed data

Chart MedinCell

Dynamic Chart

Latest news about MedinCell

Medincell: share price falls after disappointing clinical study CF
Transcript : MedinCell S.A. - Special Call
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial CI
Medincell: share price rises on resumption of trading CF
CAC40: remains in green in a neglected market CF
Medincell: positive results in schizophrenia CF
Medincell Listing Temporarily Suspended on Euronext Paris MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study RE
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia CI
CAC40: in green, builds on previous day's momentum CF
Medincell: listing suspended pending a press release CF
Medincell: share price rises following agreement with AbbVie CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies CI
Medincell: Unitaid grant to combat malaria CF
More news

Latest transcript on MedinCell

Logo MedinCell
MedinCell S.A. - Special Call
More transcripts

Analyst Recommendations on MedinCell

MedinCell: share price continues to rise, Jefferies to buy CF
MedinCell: share price surges, broker in support CF
MEDINCELL : Oddo raises its target price on the stock CF
More recommendations

Press releases MedinCell

Medincell: Publication of the Financial Results for the 2023-2024 Fiscal Year and Videoconference on Monday, June 10, 2024 BU
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate) BU
Medincell: Update of the 2024 Financial Calendar BU
Medincell to Present at the 2024 Jefferies Global Healthcare Conference, June 4 to 6, 2024, New York BU
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial BU
More press releases

News in other languages on MedinCell

Medincell : Publication des résultats financiers de l’exercice 2023-2024 et vidéoconférence, le lundi 10 juin 2024
Fais-nous rêver, Christine
En Direct des Marchés : Sanofi, Airbus, Thales, Atos, Casino, Tesla, Aramco, Valneva...
Le partenaire de Medincell, Teva, a présenté de nouvelles données soutenant le passage d’Invega Sustenna® (palmitate de palipéridone) à UZEDY® pour le traitement de la schizophrénie
Medincell : Mise à jour du calendrier financier 2024
More news

Managers and Directors - MedinCell

Managers TitleAgeSince
Christophe Douat CEO
 Chief Executive Officer 60 03-01-08
Stéphane Postic DFI
 Director of Finance/CFO 50 23-08-31
Adolfo Lopez-Noriega CTO
 Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Sabri Markabi BRD
 Director/Board Member - 17-07-04
Tone Kvåle BRD
 Director/Board Member 55 22-06-12
Virginie Lleu BRD
 Director/Board Member - 16-05-24
More insiders

Company Profile

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
2024-06-25 - Q4 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for MedinCell

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.12 EUR
Average target price
18.44 EUR
Spread / Average Target
+21.96%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
NOVARTIS AG Stock Novartis AG
+11.88% 216B
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. Stock